Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.60 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | LTA4H | P09960 | 4/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211781 | 0.95 | CYSLTR2 (0.55) | CYSLTR2CYSLTR1BRD4FAAHMAOA | |
| SCHEMBL20211766 | 0.95 | CYSLTR2 (0.55) | CYSLTR2CYSLTR1BRD4FAAHMAOA | |
| SCHEMBL20211726 | 0.87 | NPC1 (0.51) | CYSLTR2CYSLTR1MAOAMAOBLTA4H | |
| SCHEMBL14021831 | 0.87 | NPC1 (0.53) | CYSLTR2CYSLTR1BRD4MAOAMAOB | |
| SCHEMBL15399905 | 0.85 | BRD4 (0.50) | CYSLTR2CYSLTR1BRD4FAAHLTA4H | |
| SCHEMBL385690 | 0.84 | PPARA (0.58) | MAOAMAOBALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL10054169 | 0.84 | L3MBTL1 (0.62) | CYSLTR2CYSLTR1BRD4FAAHALDH1A1 | |
| SCHEMBL6313868 | 0.84 | MAOA (0.46) | CYSLTR2CYSLTR1MAOAMAOBALDH1A1 | |
| SCHEMBL527763 | 0.83 | MAOA (0.51) | CYSLTR2CYSLTR1MAOAMAOBALDH1A1 | |
| SCHEMBL5883241 | 0.83 | BRD4 (0.48) | CYSLTR2CYSLTR1BRD4FAAHLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2591795-B1 | RNA targeting compounds and methods for making and using same | UNIV NEW YORK STATE RES FOUND (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9260476-B2 | RNA targeting compounds and methods for making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2016-02-16 | — | — | US | disclosed |
| US-9150612-B2 | RNA targeting compounds and methods for making and using same | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140212945-A1 | RNA TARGETING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2591795-A1 | RNA targeting compounds and methods for making and using same | The Research Foundation Of State University Of New York (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2129388-B1 | RNA TARGETING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | UNIV NEW YORK STATE RES FOUND | 2012-09-12 | — | — | EP | disclosed |
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| EP-2129388-A2 | RNA TARGETING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | The Research Foundation Of State University Of New York (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20080227213-A1 | Comprising polymer backbone and two or more pendant RNA binding ligands; myotonic dystrophy | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2008-09-18 | — | — | US | disclosed |
| WO-2008103489-A2 | RNA TARGETING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-08-28 | — | — | WO | disclosed |
| US-4962203-A | ANTIASTHMATIC, ANTIALLERGENIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROST CANADA, INC. (CA) | 1990-10-09 | — | — | US | disclosed |
| EP-0206751-A2 | 2-Substituted quinolines, their preparation and use | MERCK FROSST CANADA INC. (CA) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140212945-A1 | RNA TARGETING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | SNRPE, POLRMT, NSUN3 | CYSLTR2 4529/4885CYSLTR1 4594/4885BRD4 2372/4885 |
| US-20090036457-A1 | Utilities of olefin derivatives | APOL1, APOB, NR1H2 | CYSLTR2 1385/4885CYSLTR1 1771/4885BRD4 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.